Big Gain For Avenue Therapeutics, Inc.
Avenue Therapeutics, Inc. (ATXI:NASDAQ) rocketted at $7.26, representing a gain of 106.3%. On Tue, Sep 27, 2022, ATXI:NASDAQ hit a New 2-Week High of $7.26. The stock got featured on our News Catalysts scanner on Fri, Sep 23, 2022 at 12:13 PM in the 'SPLIT' category. From Tue, Sep 13, 2022, the stock recorded 40.00% Up Days and 36.36% Green Days
The stock spiked on Tue, Sep 27, 2022 at $11.12 with a volume of 58M+.
About Avenue Therapeutics, Inc. (ATXI:NASDAQ)
Avenue Therapeutics Inc is a specialty pharmaceutical company focused on the development and commercialization of an intravenous, or IV, formulation of tramadol HCl, or IV Tramadol, for the management of moderate to moderately severe postoperative pain.
Top 10 Gainers:
- Avenue Therapeutics, Inc. (ATXI:NASDAQ), 106.25%
- Scienjoy Holding Corporation (SJ:NASDAQ), 47.9%
- Sonendo Inc. (SONX:NYSE), 42.74%
- X4 Pharmaceuticals, Inc. (XFOR:NASDAQ), 40.18%
- Antelope Enterprise Holdings Limited (AEHL:NASDAQ), 37.46%
- Grove Collaborative Holdings Inc. Class A (GROV:NYSE), 35.47%
- InMed Pharmaceuticals Inc. (INM:NASDAQ), 31.31%
- AN2 Therapeutics Inc. (ANTX:NASDAQ), 31.13%
- Intelligent Living Application Group Inc. (ILAG:NASDAQ), 28.43%
- Harrow Health, Inc. (HROW:NASDAQ), 27.86%